Enterprise Value
0.00
Cash
52.2M
Avg Qtr Burn
N/A
Short % of Float
4.22%
Insider Ownership
2.64%
Institutional Own.
38.89%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DSUVIA (sufentanil) Details Post operative acute pain | Approved Quarterly sales | |
Nafamostat (Niyad™) Details Medical device | Phase 3 Data readout | |
Zalviso US (sufentanil) Details Post operative acute pain | Failed Discontinued |